Anebulo Pharmaceuticals (ANEB) Accumulated Expenses (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Accumulated Expenses of $374258.0 for Q4 2025, up 172.67% year-over-year from $137259.0 in Q4 2024, and up 5.05% quarter-over-quarter from $356282.0 in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Accumulated Expenses (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Accumulated Expenses for 6 consecutive years, with $374258.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses rose 172.67% year-over-year to $374258.0; the TTM figure through Dec 2025 stood at $374258.0 (up 172.67% YoY), while the FY2025 annual figure was $263513.0, up 153.0% from the prior year.
- Accumulated Expenses advanced to $374258.0 in Q4 2025 per ANEB's latest filing, from $356282.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $694877.0 in Q4 2023 and bottomed at $2500.0 in Q1 2022.
- Historically, Accumulated Expenses has averaged $245378.5 across 5 years, with a median of $192922.5 in 2021.
- Annual changes were most pronounced in 2022 — Accumulated Expenses slumped 98.82% — and 2023, when it surged 11819.96%.
- Anebulo Pharmaceuticals' Accumulated Expenses stood at $7000.0 in 2021, then surged by 4115.81% to $295107.0 in 2022, then soared by 135.47% to $694877.0 in 2023, then plunged by 80.25% to $137259.0 in 2024, then surged by 172.67% to $374258.0 in 2025.
- Business Quant data shows ANEB's Accumulated Expenses at $374258.0 in Q4 2025, $356282.0 in Q3 2025, and $263513.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 374,258.00 |
| Sep 30, 2025 | 356,282.00 |
| Jun 30, 2025 | 263,513.00 |
| Mar 31, 2025 | 18,658.00 |
| Dec 31, 2024 | 137,259.00 |
| Sep 30, 2024 | 317,083.00 |
| Jun 30, 2024 | 104,157.00 |
| Mar 31, 2024 | 625,401.00 |
| Dec 31, 2023 | 694,877.00 |
| Sep 30, 2023 | 116,200.00 |
| Jun 30, 2023 | 534,256.00 |
| Mar 31, 2023 | 297,999.00 |
| Dec 31, 2022 | 295,107.00 |
| Sep 30, 2022 | 174,706.00 |
| Jun 30, 2022 | 131,703.00 |
| Mar 31, 2022 | 2,500.00 |
| Dec 31, 2021 | 7,000.00 |
| Sep 30, 2021 | 113,887.00 |
| Jun 30, 2021 | 131,585.00 |
| Mar 31, 2021 | 211,139.00 |